10-Q 1 c67545e10-q.txt QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: DECEMBER 31, 2001 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From __________ to __________. Commission File Number: 0-27120 KENSEY NASH CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 36-3316412 (State or other jurisdiction (IRS Employer Identification No.) of incorporation or organization) MARSH CREEK CORPORATE CENTER, 55 EAST UWCHLAN AVENUE, EXTON, PENNSYLVANIA 19341 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (610) 524-0188 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- As of January 31, 2002, there were outstanding 10,714,544 shares of Common Stock, par value $.001, of the registrant. KENSEY NASH CORPORATION QUARTER ENDED DECEMBER 31, 2001 INDEX
PAGE ---- PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS Consolidated Balance Sheets as of December 31, 2001 (Unaudited) and June 30, 2001......................... 3 Consolidated Statements of Operations for the three and six months ended December 31, 2001 and 2000 (Unaudited).......................................................... 4 Consolidated Statements of Stockholders' Equity as of December 31, 2001 (Unaudited) and June 30, 2001............................... 5 Consolidated Statements of Cash Flows for the six months ended December 31, 2001 and 2000 (Unaudited)............... 6 Notes to Consolidated Financial Statements (Unaudited).......................... 7 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS............................................ 10 PART II - OTHER INFORMATION ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K......................................................... 18 SIGNATURES................................................................................................. 19
2 PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS KENSEY NASH CORPORATION CONSOLIDATED BALANCE SHEETS --------------------------------------------------------------------------------
DECEMBER 31, ASSETS 2001 JUNE 30, CURRENT ASSETS: (UNAUDITED) 2001 ------------ ------------ Cash and cash equivalents $ 6,241,383 $ 2,841,963 Investments 25,716,804 24,164,887 Trade receivables, net of allowance for doubtful accounts of $26,456 and $1,000 at December 31, 2001 and June 30, 2001, respectively 2,412,362 4,623,456 Royalties receivable 2,356,539 2,270,091 Officer loans 1,207,299 1,170,276 Other receivables (including approximately $335,545 and $41,000 at December 31, 2001 and June 30, 2001, respectively, due from employees) 536,217 244,601 Inventory 2,192,983 1,321,511 Deferred tax asset, current portion 1,163,727 2,318,741 Prepaid expenses and other 1,050,254 512,099 ------------ ------------ Total current assets 42,877,568 39,467,625 ------------ ------------ PROPERTY, PLANT AND EQUIPMENT, AT COST: Leasehold improvements 5,676,760 5,676,760 Machinery, furniture and equipment 10,240,453 7,853,177 Construction in progress 863,483 1,606,181 ------------ ------------ Total property, plant and equipment 16,780,696 15,136,118 Accumulated depreciation (7,027,365) (6,105,575) ------------ ------------ Net property, plant and equipment 9,753,331 9,030,543 ------------ ------------ OTHER ASSETS: Restricted investments 2,113,072 2,231,251 Property under capital leases, net 1,525 Deferred tax asset, non-current portion 2,105,837 2,125,407 Acquired patents, net of accumulated amortization of $1,028,180 and $896,666 at December 31, 2001 and June 30, 2001, respectively 3,068,187 3,199,700 Goodwill, net of accumulated amortization of $100,037 at December 31, 2001 and June 30, 2001 3,284,303 3,284,303 ------------ ------------ Total other assets 10,571,399 10,842,186 ------------ ------------ TOTAL $ 63,202,298 $ 59,340,354 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 1,446,737 $ 1,891,484 Accrued expenses 909,431 544,268 Current portion of debt and capital lease obligations 943,200 910,738 Deferred revenue 232,194 123,352 ------------ ------------ Total current liabilities 3,531,562 3,469,842 ------------ ------------ LONG TERM PORTION OF DEBT AND CAPITAL LEASE OBLIGATIONS 1,829,026 2,309,385 ------------ ------------ Total liabilities 5,360,588 5,779,227 ------------ ------------ COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY: Preferred stock, $.001 par value, 100,000 shares authorized, no shares issued or outstanding at December 31, 2001 and June 30, 2001 Common stock, $.001 par value, 25,000,000 shares authorized, 10,713,384 and 10,509,431 shares issued and outstanding at December 31, 2001 and June 30, 2001, respectively 10,713 10,509 Capital in excess of par value 66,024,280 63,974,745 Accumulated deficit (8,003,865) (10,196,713) Accumulated other comprehensive income (189,418) (227,414) ------------ ------------ Total stockholders' equity 57,841,710 53,561,127 ------------ ------------ TOTAL $ 63,202,298 $ 59,340,354 ============ ============
See notes to consolidated financial statements. 3 KENSEY NASH CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) --------------------------------------------------------------------------------
Three Months Ended Six Months Ended December 31, December 31, ---------------------------- ---------------------------- 2001 2000 2001 2000 REVENUES: Net sales $ 4,257,699 $ 3,096,225 $ 8,850,878 $ 5,680,965 Research and development 175,299 115,000 280,733 116,843 Royalty income 2,358,267 1,925,471 4,570,100 3,922,455 ------------ ------------ ------------ ------------ Total revenues 6,791,265 5,136,696 13,701,711 9,720,263 ------------ ------------ ------------ ------------ OPERATING COSTS AND EXPENSES: Cost of products sold 2,029,582 1,611,932 4,165,209 3,326,755 Research and development 2,366,136 1,578,222 5,110,663 3,215,272 Selling, general and administrative 995,906 794,903 1,906,334 1,311,530 In-process research and development charge 7,593,597 7,593,597 ------------ ------------ ------------ ------------ Total operating costs and expenses 5,391,624 11,578,654 11,182,206 15,447,154 ------------ ------------ ------------ ------------ INCOME (LOSS) FROM OPERATIONS 1,399,641 (6,441,958) 2,519,505 (5,726,891) ------------ ------------ ------------ ------------ OTHER INCOME: Interest income 478,985 480,360 955,070 1,019,062 Interest expense (59,610) (75,907) (120,234) (101,610) Other (2,275) 400 (6,481) 400 ------------ ------------ ------------ ------------ Total other income - net 417,100 404,853 828,355 917,852 ------------ ------------ ------------ ------------ INCOME (LOSS) BEFORE INCOME TAXES 1,816,741 (6,037,105) 3,347,860 (4,809,039) Income tax expense (626,776) (1,155,012) ------------ ------------ ------------ ------------ NET INCOME (LOSS) $ 1,189,965 $ (6,037,105) $ 2,192,848 $ (4,809,039) ============ ============ ============ ============ BASIC EARNINGS (LOSS) PER SHARE $ 0.11 $ (0.58) $ 0.21 $ (0.46) ============ ============ ============ ============ DILUTED EARNINGS (LOSS) PER SHARE $ 0.11 $ (0.58) $ 0.20 $ (0.46) ============ ============ ============ ============ WEIGHTED AVERAGE COMMON SHARES OUTSTANDING 10,664,773 10,459,568 10,601,932 10,457,993 ============ ============ ============ ============ DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING 11,322,039 10,459,568 11,207,860 10,457,993 ============ ============ ============ ============
See notes to consolidated financial statements. 4 KENSEY NASH CORPORATION CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY --------------------------------------------------------------------------------
ACCUMULATED CAPITAL OTHER COMPREHENSIVE COMMON STOCK IN EXCESS ACCUMULATED COMPREHENSIVE INCOME / ------------------- OF PAR DEFICIT (LOSS) / GAIN (LOSS) TOTAL SHARES AMOUNT VALUE BALANCE, JUNE 30, 1999 7,470,710 $ 7,470 $37,697,452 $(18,562,619) $(241,402) $18,900,901 Shares issued upon Secondary Offering 2,959,000 2,959 26,247,007 26,249,966 Secondary Offering costs (501,241) (501,241) Exercise of stock options 25,789 26 246,824 246,850 Net income 4,749,164 $4,749,164 4,749,164 Comprehensive loss (241,284) (241,284) (241,284) ---------- Comprehensive income $4,507,880 ========== ---------- ------- ---------- ------------ -------- ---------- BALANCE, JUNE 30, 2000 10,455,499 10,455 63,690,042 (13,813,455) (482,686) 49,404,356 ---------- ------- ---------- ------------ -------- ---------- Secondary Offering costs (212,681) (212,681) Exercise of stock options 53,932 54 497,384 497,438 Net income 3,616,742 $3,616,742 3,616,742 Comprehensive gain 255,272 255,272 255,272 ---------- Comprehensive income $3,872,014 ---------- ------- ----------- ------------- --------- ========== ----------- BALANCE, JUNE 30, 2001 10,509,431 $10,509 $63,974,745 $(10,196,713) $(227,414) $53,561,127 ---------- ------- ----------- ------------- --------- ----------- Exercise of stock options 203,953 204 2,049,535 2,049,739 Net income 2,192,848 $2,192,848 2,192,848 Comprehensive loss 37,996 37,996 37,996 ---------- Comprehensive income $2,230,844 ---------- ------- ----------- ------------- --------- ========== ----------- BALANCE, DECEMBER 31, 2001 10,713,384 $10,713 $66,024,280 $ (8,003,865) $(189,418) $57,841,710 ========== ======= =========== ============= ========= ===========
5 KENSEY NASH CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) --------------------------------------------------------------------------------
SIX MONTHS ENDED DECEMBER 31, ----------------------------- 2001 2000 OPERATING ACTIVITIES: Net income (loss) $ 2,192,848 $ (4,809,039) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization 1,054,828 934,783 In-process research and development charge 7,593,597 Changes in assets and liabilities which provided (used) cash: Accounts receivable 1,796,007 84,944 Deferred tax asset 1,174,584 Prepaid expenses and other current assets (538,155) (105,586) Inventory (871,472) (350,382) Accounts payable and accrued expenses (79,584) (589,706) Deferred revenue 108,842 (288,850) ------------ ------------ Net cash provided by operating activities 4,837,898 2,469,761 ------------ ------------ INVESTING ACTIVITIES: Additions to property, plant and equipment (1,644,578) (1,248,063) Acquisition of THM Biomedcal, Inc. (6,771,087) Redemption of investments 9,535,000 Purchase of investments (10,930,742) (4,153,462) ------------ ------------ Net cash used in investing activities (3,040,320) (12,172,612) ------------ ------------ FINANCING ACTIVITIES: Principal payments under capital leases (1,937) (5,898) Repayments of long term debt (445,960) (186,088) Secondary offering costs (212,326) Exercise of stock options 2,049,739 37,137 ------------ ------------ Net cash provided by (used in) financing activities 1,601,842 (367,175) ------------ ------------ INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 3,399,420 (10,070,026) CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 2,841,963 24,117,502 ------------ ------------ CASH AND CASH EQUIVALENTS, END OF PERIOD $ 6,241,383 $ 14,047,476 ============ ============ SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest $ 120,234 $ 101,610 ============ ============ Cash paid for income taxes $ 80,000 $ ============ ============
See notes to consolidated financial statements. 6 KENSEY NASH CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) NOTE 1 --CONSOLIDATED FINANCIAL STATEMENTS BASIS OF PRESENTATION The consolidated balance sheet at December 31, 2001, the consolidated statements of operations for the three and six months ended December 31, 2001 and 2000 and the consolidated statements of cash flows for the six months ended December 31, 2001 and 2000 have been prepared by Kensey Nash Corporation (the Company) and have not been audited by the Company's independent auditors. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at December 31, 2001 and for all periods presented have been made. Certain information and note disclosures normally included in the Company's annual financial statements, prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted. These consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's June 30, 2001 consolidated financial statements filed with the Securities and Exchange Commission on Form 10-K. The results of operations for the period ended December 31, 2001 are not necessarily indicative of operating results for the full year. PRINCIPLES OF CONSOLIDATION AND BASIS OF PRESENTATION The consolidated financial statements include the accounts of Kensey Nash Corporation and Kensey Nash Holding Company. All intercompany transactions and balances have been eliminated. Kensey Nash Holding Company, incorporated in Delaware on January 8, 1992, was formed to hold title to certain Company patents and has no operations. The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America necessarily requires management to make estimates and assumptions. These estimates and assumptions, which may differ from actual results, will affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expense during the period. CASH AND CASH EQUIVALENTS Cash and cash equivalents represent cash in banks and short-term investments having an original maturity of less than six months. EXPORT SALES There were $104,617 and $264,489 in export sales from the Company's U.S. operations to unaffiliated customers in Europe in the three and six months ended December 31, 2001, respectively. There were no export sales in the three and six months ended December 31, 2000. REVENUE RECOGNITION The Company recognizes revenue under the provisions of Staff Accounting Bulletin (SAB) No. 101, Revenue Recognition in Financial Statements (SAB 101). Accordingly, sales revenue is recognized when the related product is shipped. Revenue under research and development contracts is recognized as the related costs are incurred. Advance payments received for products or services are recorded as deferred revenue and are recognized when the product is shipped or services are performed. The Company receives a royalty (historically 12%, became 9% in October 2000 when a cumulative 1,000,000 units had been sold) on every Angio-Seal unit sold by our partner, St. Jude Medical. We recognize the revenue, in accordance with the Licensing Agreement between the Company and St. Jude Medical, at the end of each month when St. Jude Medical advises us of their total Angio-Seal sales dollars for the month. Royalty payments are received within 45 days of the end of each calendar quarter. 7 EARNINGS PER SHARE Earnings per share are calculated in accordance with SFAS No. 128, Earnings per Share which requires the Company to report both basic and diluted earnings per share (EPS). Basic and diluted EPS are computed using the weighted average number of shares of common stock outstanding, with common equivalent shares from options included in the diluted computation when their effect is dilutive. COMPREHENSIVE INCOME The Company accounts for comprehensive income under the provisions of SFAS No. 130, Reporting Comprehensive Income (SFAS 130). Accordingly, accumulated other comprehensive loss is shown in the consolidated statements of shareholders' equity at December 31, 2001, June 30, 2001, 2000 and 1999, and is solely comprised of unrealized gains and losses on the Company's available-for-sale securities. The tax effect of other comprehensive income for the six months ended December 31, 2001 and for the fiscal years ended June 30, 2001 and 2000 was $98,000, $117,000 and $0, respectively. RECENT PRONOUNCEMENTS In June 2001 the Financial Accounting Standards Board (FASB) issued SFAS No. 141, Business Combinations (SFAS 141), and SFAS No. 142, Goodwill and Other Intangible Assets (SFAS 142), which were effective July 1, 2001 for the Company, as the Company early adopted SFAS 142. SFAS 141 requires that the purchase method of accounting be used for all business combinations subsequent to June 30, 2001 and specifies criteria for recognizing intangible assets acquired in a business combination. SFAS 142 requires that goodwill and intangible assets with indefinite useful lives no longer be amortized upon adoption of this standard, but instead be tested for impairment at least annually. Intangible assets with definite useful lives will continue to be amortized over their respective useful lives. The Company recorded $100,036 in goodwill amortization expense for the year ended June 30, 2001. Goodwill amortization expense for the year ending June 30, 2002 would have been $205,111 if the Company had decided not to early adopt SFAS 142. The early adoption of SFAS 142 did not result in the reclassification of any intangible assets, changes in the amortization periods for those intangible assets with definite lives or in the impairment of any intangible assets. In accordance with the provisions of SFAS 142, the Company has done an evaluation of goodwill for impairment and determined that no impairment has occurred as of December 31, 2001. The FASB issued SFAS No. 143, Accounting for Asset Retirement Obligations (SFAS 143) and SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (SFAS 144), which will both be effective for the Company's fiscal year beginning July 1, 2002. The Company is currently evaluating all of the provisions of SFAS 143 and SFAS 144 and is, therefore, not presently able to quantify the impact of adoption. NOTE 2 -- INVENTORY Inventory is stated at the lower of cost (determined by the average cost method, which approximates first-in, first-out) or market. Inventory primarily includes the cost of material utilized in the processing of the Company's products and is as follows: DECEMBER 31, JUNE 30, 2001 2001 ------------ ---------- Raw materials $1,726,634 $1,062,626 Work in process 466,349 240,451 Finished Goods 18,434 ---------- ---------- Total $2,192,983 $1,321,511 ========== ========== NOTE 3 -- COMMITMENTS AND CONTINGENCIES As of December 31, 2001, the Company has pledged $2,113,072 in investments as collateral to secure certain bank loans to officers which were used by such officers for the payment of taxes incurred as the result of the receipt of Common Stock at the Company's initial public offering in December 1995. In exchange for the Company pledging collateral for such loans, each affected officer has pledged their Common Stock as collateral to the Company. The loans are repayable at the sooner of the sale of the officer's stock or December 2002. The balance outstanding on such officer loans was $2,030,620 at December 31, 2001. 8 NOTE 4 -- INCOME TAXES As of June 30, 2001, the Company had net operating loss (NOL) carryforwards for federal and state tax purposes totaling $5.4 and $20.0 million, respectively. A portion of the NOL may be subject to various statutory limitations as to its usage. The Company recognized income tax expense for the first time in the quarter ended September 30, 2001 as a result of the recognition of a tax benefit in fiscal year 2001 related to the realization of certain deferred tax assets which had previously been offset by a valuation allowance. NOTE 5 -- THM ACQUISITION On September 1, 2000 the Company acquired THM Biomedical, Inc. (THM), a developer of porous, biodegradable, tissue-engineering products for the repair and replacement of musculoskeletal tissues, for approximately $10.5 million plus acquisition costs of approximately $239,000. The transaction was financed with $6.6 million of the Company's cash and a note payable to the shareholders of THM in the amount of $4.5 million (the Acquisition Obligation). The Acquisition Obligation is due in equal quarterly installments of $281,000 beginning on December 31, 2000 and ending on September 30, 2004. Accordingly, the present value of the cash payments (discounted based upon the Company's available borrowing rate of 7.5%) of $3.8 million was recorded as a liability on the Company's financial statements, with a remaining balance of $2.8 million at December 31, 2001. The acquisition has been accounted for under the purchase method of accounting and THM's results of operations are included in those of the Company since the date of acquisition. The purchase price has been allocated to the assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. The allocation has resulted in goodwill of approximately $3.4 million, which was originally being amortized, on a straight-line basis over 17 years. The following is a summary of the allocation (in thousands): Assets $ 400 Accrued expenses and other liabilities (702) In-process research and development 7,594 Excess of cost over net assets acquired (goodwill) 3,384 ------- $10,676 ======= A significant portion of the purchase price was identified as acquired in-process research and development (IPR&D). The valuation of IPR&D was performed in an independent appraisal using proven valuation procedures and techniques and represents the estimated fair market value based on risk-adjusted cash flows related to the IPR&D programs. The IPR&D consists of four primary research and development programs that are expected to reach completion between late 2002 and 2005. At the date of acquisition, the development of these programs had not yet reached technological feasibility and the IPR&D had no alternative future uses. Accordingly, these costs were immediately expensed in the consolidated statement of operations on the acquisition date. The following unaudited pro-forma financial information assumes that the acquisition had occurred as of the beginning of the earliest period presented: SIX MONTHS SIX MONTHS ENDED ENDED 12/31/01 12/31/00 ------------ ------------ Total revenue $ 13,701,711 $ 10,987,158 ============ ============ IPR&D Charge $ -- $ (7,593,597) ============ ============ Net income $ 2,192,848 $ (3,834,430) ============ ============ Basic earnings per share $ 0.21 $ (0.37) ============ ============ Diluted earnings per share $ 0.20 $ (0.37) ============ ============ 9 These pro forma results are based on certain assumptions and estimates. The pro forma results do not necessarily represent results that would have occurred if the acquisition had taken place at the beginning of the specified periods, nor are they indicative of the results of future combined operations. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis should be read in conjunction with our financial statements and the related notes included in this report. OVERVIEW We were founded in 1984 and our common stock became publicly traded in December 1995. We have been profitable in our last sixteen fiscal quarters (excluding the one time IPR&D charge taken in our second quarter of fiscal year 2001). Revenues Our revenues consist of three components: net sales, research and development revenue and royalty income. Net Sales. Net sales is comprised of absorbable biomaterials products and Angio-Seal(TM)devices we manufactured and sold to St. Jude Medical. Biomaterials. The biomaterials component of net sales represents the sale of our biomaterials products to customers for use in the following markets: orthopedics, cardiology, drug/biologics delivery, dental and wound care. In 1997, our biomaterials sales were comprised almost 100% of the absorbable collagen and polymer components of the Angio-Seal supplied to our strategic alliance partner. Since that time we have experienced significant sales growth in our biomaterials products as we have brought in new customers, increased sales to those customers over the past four years, assisted in the development of new product offerings and expanded our marketing activities. We believe this growth will continue because of greater acceptance by the medical community of biomaterials and technological advances which have expanded the applications for our biomaterials products. In the three and six months ended December 31, 2001, the Angio-Seal components represent only 33% and 38% of our total biomaterial sales, respectively. Angio-Seal. In August 2000, St. Jude Medical transitioned the manufacturing of 6F Angio-Seal devices from Kensey Nash to their facility. We do not expect any revenue from the manufacture of completed Angio-Seal devices in the future. The manufacture of the 6F Angio-Seal represented $358,000, or 6% of our total net sales for the six months ended December 31, 2000. For the six months ended December 31, 2001, we experienced 56% growth in our net sales despite the loss of the 6F Angio-Seal device manufacturing business. Research and Development Revenue. Research and development revenue in the three and six months ended December 31, 2000 was derived from a National Institute of Standards & Technology (NIST) grant, under which we are researching cartilage regeneration utilizing our porous tissue matrix (PTM) technology. This project will continue through early fiscal year 2003. This grant was acquired in conjunction with our acquisition of THM in September 2000. In addition, in October 2001 we received a second NIST grant, under which we are researching a synthetic vascular graft also utilizing our porous tissue matrix (PTM) technology. This project will continue through early fiscal year 2005. Royalty Income. We receive a royalty on every Angio-Seal unit sold worldwide. We anticipate sales of the Angio-Seal will continue to grow as St. Jude Medical continues to expand its sales and marketing efforts and releases future generations of the Angio-Seal. As a result, royalty income will continue to be a significant source of revenue. The unit growth for the three and six months ended December 31, 2001 over the three and six months ended December 31, 2000 was partially offset by the reduction in our royalty rate, from 12% to 9%, in accordance with our licensing agreements. This rate reduction occurred during the quarter ended December 31, 2000, when a cumulative one million Angio-Seal units had been sold. There will be one further decrease in the royalty rate, to 6%, upon reaching four million cumulative units sold. We anticipate this next reduction will not occur until fiscal year 2005. 10 Cost of Products Sold. We have experienced an overall increase in gross margin during the three and six months ended December 31, 2001 reflecting the higher volume of our biomaterials products and the elimination of lower margin Angio-Seal device sales. This increase in sales volume allows us to spread our fixed costs of manufacturing over a greater number of units. We anticipate our gross margin will continue to improve as our biomaterials sales levels increase and our product mix becomes more favorable. Research and Development Expense. Research and development expense consists of expenses incurred for the development of our proprietary technologies such as the TriActiv(TM) system, absorbable biomaterials products and technologies and other development programs, including expenses under the NIST program. While we no longer perform research and development on the Angio-Seal, the progression of the TriActiv system into the clinical trial phase and our continued development of proprietary biomaterials products and technologies has offset this decrease. In January 2002, we received CE Mark approval from the European regulatory authority for the TriActiv system, which allows commercial sale of the product in the European union. We anticipate research and development expense will continue to increase as we pursue commercialization of the TriActiv system in the United States as well as explore opportunities for our other technologies. Selling, General and Administrative. Selling, general and administrative expenses include general and administrative costs as well as costs related to the marketing of our products. During the three and six months ended December 31, 2001 and 2000, the costs of our patent litigation are also included within selling, general and administrative expenses. The marketing component of selling, general and administrative expenses has increased as we move toward commercialization of the TriActiv system in both Europe and the United States. We received CE Mark approval for the TriActiv System in January 2002. During the quarter ended December 31, 2001 we established a subsidiary in Germany and hired a Vice President of European sales. We will continue to add personnel to our European marketing team as we will be selling the TriActiv system direct to the market in Germany and are in the process of identifying distributors for the rest of Europe. We anticipate sales and marketing expenses will continue to increase as we will launch the product in Europe in our fourth fiscal quarter of 2002. We also continue to evaluate opportunities for commercialization of the TriActiv system in the United States and expand the marketing efforts for our biomaterials business. RESULTS OF OPERATIONS COMPARISON OF THREE MONTHS ENDED DECEMBER 31, 2001 AND 2000 Revenues. Revenues increased 32% to $6.8 million in the three months ended December 31, 2001 from $5.1 million in the three months ended December 31, 2000. Net sales of products increased 38%, to $4.3 million from $3.1 million for the three months ended December 31, 2001 and 2000, respectively. Net sales for the three months ended December 31, 2001 and 2000 consisted entirely of biomaterials sales. The final shipment of Angio-Seal devices was made in the three months ended September 30, 2000. Research and Development Revenues. Research and development revenues increased 52% to $175,000 from $115,000 for the three months ended December 30, 2001 and 2000, respectively. Prior year revenues were generated under the NIST articular cartilage development grant acquired in conjunction with the THM acquisition. The increase over the prior year reflects the addition of a second NIST grant for synthetic vascular graft research in October 2001. Royalty Income. Royalty income increased 22% to $2.4 million from $1.9 million in the three months ended December 31, 2001 and 2000, respectively. This increase was achieved despite the contractual 25% reduction in the Angio-Seal royalty rate from 12% to 9% during the quarter ended December 31, 2000 and reflects a greater number of units sold as well as an increase in average selling price for the Angio-Seal. Royalty units increased 34% as approximately 153,000 Angio-Seal units were sold to end-users during the three months ended December 31, 2001 compared to approximately 114,000 units sold during the three months ended December 31, 2000. This unit increase was due to St. Jude Medical's increased sales and marketing efforts and continued strong sales of the 6F and 8F Angio-Seal in the worldwide market. Cost of Products Sold. Cost of products sold increased 26% to $2.0 million in the three months ended December 31, 2001 from $1.6 million in the three months ended December 31, 2000. While overall cost of products sold increased, 11 gross margin also increased to 52% from 48%. This increase reflects the higher margins on our biomaterials products as well as continued allocation of overhead across greater sales volumes, which results in a decrease in per unit costs. Research and Development Expense. Research and development expense increased 50% to $2.4 million in the three months ended December 31, 2001 from $1.6 million in the three months ended December 31, 2000. This increase was mainly attributable to our continued development efforts on the TriActiv system, including clinical trial expenses. We also continued to expand our development efforts on our biomaterials products including our work under the NIST articular cartilage development grant. We expect research and development expense to increase as we investigate and develop new products, conduct clinical trials and seek regulatory approvals for our proprietary products. Selling, General and Administrative. Selling, general and administrative expense increased 25% to $996,000 in the three months ended December 31, 2001 from $795,000 in the three months ended December 31, 2000. This increase was primarily the result of sales and marketing expenses which increased to $325,000 in the three months ended December 31, 2001 from $190,000 in the three months ended December 31, 2000 related to primarily to increased marketing efforts on the TriActiv system. In addition, general and administrative expenses increased $69,000, to $655,000 in the three months ended December 31, 2001 from $586,000 in the three months ended December 31, 2000. This was primarily attributable to $65,000 of increased personnel costs in our human resources, management information systems (MIS) and finance departments to support our continued growth. Litigation expenses for our patent infringement suit, which are included in selling, general and administrative expense, decreased to $16,000 for the three months ended December 31, 2001 from $19,000 from the three months ended December 31, 2000. Net Interest Income. Interest expense decreased 21% to $60,000 in the three months ended December 31, 2001 from $76,000 in the three months ended December 31, 2000. This decrease was the result of a lower principal balance on the THM Biomedical acquisition obligation as we have made four quarterly payments to date. Interest income decreased slightly to $479,000 in the three months ended December 31, 2001 from $480,000 in the three months ended December 31, 2000. Although our cash and investment balances have increased, this has been offset by lower interest rates. Other Non-Operating Income (Expense). Other non-operating expense was $2,000 for the three months ended December 31, 2001 and represents a loss on the disposal of fixed assets. Net Income. Net income increased to $1.2 million in the three months ended December 31, 2001 from a net loss of $6.0 million in the three months ended December 31, 2000. Net income for the three months ended December 31, 2001 was the result of $1.8 million of income before income taxes and a $627,000 charge for income taxes. This is our second quarter of recognizing income tax expense as a result of the recognition of a tax benefit in fiscal year 2001 related to the realization of certain deferred tax assets which had previously been offset by a valuation allowance. The $6.0 million net loss for the three months ended December 31, 2000 was the result of the $7.6 million IPR&D charge. Prior to this charge, net income would have been $1.6 million. There was no income tax expense for this period. COMPARISON OF SIX MONTHS ENDED DECEMBER 31, 2001 AND 2000 Revenues. Revenues increased 41% to $13.7 million in the six months ended December 31, 2001 from $9.7 million in the six months ended December 31, 2000. Net sales of products increased 56%, to $8.9 million from $5.7 million for the six months ended December 31, 2001 and 2000, respectively. Biomaterials sales increased 60%, as the $8.9 million of sales for the six months ended December 31, 2001 were entirely biomaterials sales compared to $5.3 million in the six months ended December 31, 2000. The six months ended December 2000 included $358,000 of Angio-Seal device sales to St. Jude Medical. St. Jude Medical transitioned the manufacturing of these devices to their facility in August 2000. Research and Development Revenues. Research and development revenues increased 40% to $281,000 from $117,000 for the six months ended December 30, 2001 and 2000, respectively. Prior year revenues were generated under the NIST articular cartilage development grant acquired in conjunction with the THM acquisition. 12 The increase over the prior year reflects the addition of a second NIST grant for synthetic vascular graft research in October 2001. Royalty Income. Royalty income increased 17% to $4.6 million from $3.9 million in the six months ended December 31, 2001 and 2000, respectively. This increase was achieved despite the contractual 25% reduction in the Angio-Seal royalty rate, from 12% to 9%, during the quarter ended December 31, 2000 and reflects a greater number of units sold as well as an increase in average selling price for the Angio-Seal. Royalty units increased 38% as approximately 292,000 Angio-Seal units were sold to end-users during the six months ended December 31, 2001 compared to approximately 211,000 units sold during the six months ended December 31, 2000. This unit increase was due to St. Jude Medical's increased sales and marketing efforts and continued strong sales of the 6F and 8F Angio-Seal in the worldwide market. Cost of Products Sold. Cost of products sold increased 25% to $4.2 million in the six months ended December 30, 2001 from $3.3 million in the six months ended December 31, 2000. While overall cost of products sold increased, gross margin also increased to 53% from 41%. This increase reflects the high margins on our biomaterials products as well as continued allocation of overhead across greater sales volumes, which results in a decrease in per unit costs. Research and Development Expense. Research and development expense increased to 59% to $5.1 million in the six months ended December 31, 2001 from $3.2 million in the six months ended December 31, 2000. This increase was mainly attributable to our continued development efforts on the TriActiv system, including clinical trial expenses. We also continued to expand our development efforts on our biomaterials products including our work under the NIST articular cartilage and synthetic vascular graft development grants. We expect research and development expense to increase as we investigate and develop new products, conduct clinical trials and seek regulatory approvals for our proprietary products. Selling, General and Administrative. Selling, general and administrative expense increased 45% to $1.9 million in the six months ended December 31, 2001 from $1.3 million in the six months ended December 31, 2000. This increase was primarily the result of sales and marketing expenses which increased to $591,000 in the six months ended December 31, 2001 from $267,000 in the six months ended December 31, 2000 related primarily to increased marketing efforts on the TriActiv system as we prepare for the commercial launch of this product in Europe in the fourth fiscal quarter of 2002 and continue to evaluate our market strategy for the U.S. In addition, general and administrative expenses increased 24%, or $246,000, to $1.3 million in the six months ended December 31, 2001 from $1.0 million in the six months ended December 31, 2000. This was attributable to $170,000 of increased personnel costs in our human resources, management information systems (MIS) and finance departments to support our continued growth. Litigation expenses for our patent infringement suit increased to $50,000 for the six months ended December 31, 2001 from $4,000 from the six months ended December 31, 2000. These costs related to our motion for reconsideration of prior orders and subsequent filing of appeal, which occurred in November 2001. Net Interest Income. Interest expense increased 18% to $120,000 in the six months ended December 31, 2001 from $102,000 in the six months ended December 31, 2000. This increase was the result of interest expense on the THM Biomedical acquisition obligation for a full six months in the current year as opposed to four months of expense in the prior year. Interest income decreased slightly to $955,000 in the six months ended December 31, 2001 from $1.0 million in the six months ended December 31, 2000. Although our cash and investment balances have increased, this has been offset by lower interest rates. Other Non-Operating Income (Expense). Other non-operating expense was $6,000 for the six months ended December 31, 2001 and represents a loss on the disposal of fixed assets. Net Income. Net income increased to $2.2 million in the six months ended December 31, 2001 from a net loss of $4.8 million in the six months ended December 31, 2000. Net income for the six months ended December 31, 2001 was the result of $3.3 million of income before income taxes and a $1.2 million charge for income taxes. This is our first fiscal year of recognizing income tax expense as a result of the recognition of a tax benefit in fiscal year 2001 related to the realization of certain deferred tax assets which had previously been offset by a valuation allowance. The $4.8 million net 13 loss for the six months ended December 31, 2000 was the result of the $7.6 million IPR&D charge. Prior to this charge, net income would have been $2.8 million. There was no income tax expense for this period. LIQUIDITY AND CAPITAL RESOURCES Net cash provided by our operating activities was $4.8 million and $2.5 million in the six months ended December 31, 2001 and 2000, respectively. In the six months ended December 31, 2001, changes in asset and liability balances provided $1.6 million of cash, in addition to net income of $2.2 million and non-cash depreciation and amortization of $1.1 million. In the six months ended December 31, 2000, changes in asset and liability balances used $1.2 million of cash. The net loss of $4.8 million was offset by the $7.6 million and $935,000 non-cash charges for the write-off of in-process research and development and depreciation and amortization, respectively. Our cash, cash equivalents and short-term investments were $32.0 million at December 31, 2001. In addition, we had $2.1 million in restricted investment accounts. We have pledged $2.1 million in investments as collateral to secure bank loans made to employees to pay taxes incurred by these employees when they received common stock at the time of our initial public offering. In exchange for our pledging this collateral, the employees have pledged their common stock to us as collateral. We have a $4.1 million capital spending plan for fiscal 2002, of which $1.6 million has been spent primarily on machinery and equipment. These expenditures are related to the continued expansion of our manufacturing capabilities for our biomaterials and TriActiv product lines. We have a $2.8 million obligation to the shareholders of THM Biomedical, Inc., a company we acquired in September 2000 (see below). The obligation is due in equal quarterly installments of $281,250 which began on December 31, 2000 and end on September 30, 2004. We plan to continue to spend substantial amounts to fund clinical trials, to gain regulatory approvals to expand our facilities to accomodate the manufacturing of the TriActiv and our expanding base of biomaterials products and to continue to expand research and development activities, particularly for the TriActiv system and our biomaterials products. We believe our current cash and investment balances, in addition to cash generated from operations, will be sufficient to meet our operating and capital requirements through at least fiscal 2003. Our future capital requirements and the adequacy of available funds will depend, however, on numerous factors, including market acceptance of our existing and future products; the successful commercialization of products in development; progress in our product development efforts; the magnitude and scope of such efforts; progress with pre-clinical studies, clinical trials and product clearance by the FDA and other agencies, the cost and timing of our efforts to expand our manufacturing capabilities; the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; competing technological and market developments; and the development of strategic alliances for the marketing of certain of our products. There can be no assurance that we will record profits in future periods. The terms of any future equity financing may be dilutive to our stockholders and the terms of any debt financing may contain restrictive covenants, which limit our ability to pursue certain courses of action. Our ability to obtain financing is dependent on the status of our future business prospects as well as conditions prevailing in the relevant capital markets. No assurance can be given that any additional financing will be made available to us or will be available on acceptable terms should such a need arise. Our estimate of the time periods for which cash and cash equivalents will be adequate to fund operations is a forward looking statement within the meaning of Private Securities Litigation Reform Act of 1995 and is subject to risks and uncertainties. Actual results may differ materially from those contemplated in such forward-looking statements. In addition to those described above, factors which may cause such a difference are set forth under the caption "Risks Related to Our Business " as well as in our annual report on form 10-K generally. ACQUISITION OF THM BIOMEDICAL, INC. AND IN-PROCESS RESEARCH AND DEVELOPMENT CHARGE On September 1, 2000 we acquired THM Biomedical, Inc. (THM), a developer of porous, biodegradable, tissue-engineering products for the repair and replacement of muskuloskeletal tissues, for approximately $10.5 million plus acquisition costs of approximately $228,000. The transaction was financed with $6.6 million in cash and a note 14 payable to the shareholders of THM in the amount of $4.5 million (the Acquisition Obligation). The Acquisition Obligation is due in equal quarterly installments of $281,250 beginning on December 31, 2000 and ending on September 30, 2004. Accordingly, the present value of the cash payments (discounted based upon our available borrowing rate of 7.5%) of $3.9 million was recorded as a liability on the Company's financial statements, with a remaining balance of $2.8 million at December 31, 2001. The $7.6 million IPR&D charge represented the estimated fair value of purchased in-process technology which had not yet reached technological feasibility and had no alternative future use and was comprised of the following projects: Articular Cartilage ($5.4 million), Bone Fusion ($389,000), Other Bone Applications ($261,000), and Drug Delivery ($1.5 million). Each of the four projects utilizes the core open-cell poly lactic acid (OPLA) technology, a porous tissue matrix (PTM) technology developed by THM. PTM technology facilitates wound healing in both bone and soft tissue and is bioabsorbable at controlled rates for specific functions and tissues. Each of the IPR&D projects utilizes these properties of the PTM technology to address its respective market. For example, the articular cartilage project uses the PTM technology as the foundation for an articular cartilage repair and regrowth product. The total IPR&D value was determined by estimating the stage of completion of each IPR&D project at the date of the acquisition, estimating the costs to develop each IPR&D project into commercially viable products, estimating the resulting net cash flows from such projects, and discounting the net cash flows back to their present values. The discount rate in each project takes into account the uncertainty surrounding the successful development and commercialization of the purchased in-process technology. The stage of completion for all projects ranged from 48% to 72% as of the acquisition date with the weighted average completion rate approximately 56%. As of that date, the estimated costs to bring the projects under development to technological feasibility and through clinical trials were approximately $7.3 million. Since the date of the acquisition, as planned, we have primarily devoted our development efforts of PTM technology to the articular cartilage application and have expended $545,000 on such efforts through December 31, 2001. In addition, in October 2001 we received regulatory approval for a proprietary PTM based product, Improvise, which is a cement flow restrictor, with applications in the orthopedics market. We are also seeking regulatory approval on a second proprietary PTM based orthopedic product. The net cash flows from IPR&D projects were based on management's best estimates of revenue, cost of sales, research and development costs, general and administrative costs, and income taxes from such projects. These estimates were determined considering our historical experience and industry trends and averages. The cash flow estimates from sales of products incorporating these technologies are expected to commence between the fiscal years 2003 and 2005, depending on the project, with revenue growth rates in the 50% range in the immediate years following worldwide market launch, declining to the 5% range as each market nears maturity. These projections were based on our best estimates of market size and growth, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The cash flows from revenues in each period are reduced by related expenses, capital expenditures, the cost of working capital and an assigned contribution to the core technology serving as a foundation for the research and development. The discount rates used in discounting the net cash flows from purchased in-process technology were 80% for articular cartilage, 85% for bone fusion, 78% for other bone applications and 83% for drug delivery. These discount rates for each project were determined upon consideration of the stage of completion of the project, the assumptions, nature and timing of the remaining efforts for completion and risks and uncertainties of the project. Substantial further research and development, pre-clinical testing and clinical trials will be required to determine the technical feasibility and commercial viability of the products under development. There can be no assurance such efforts will be successful. If these projects are not successfully developed, our revenue and profitability may be adversely affected in future periods. We are continuously monitoring our development projects and believe that the assumptions used in the valuation of purchased in-process technology reasonably estimate the future benefits attributable to such purchased in-process technology. No assurance can be given that actual results will not deviate from those assumptions in future periods. 15 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Our interest income and expense are sensitive to changes in the general level of interest rates. In this regard, changes in interest rates affect the interest earned on our cash, cash equivalents and investments as well as interest paid on our debt. Our investment portfolio consists primarily of high quality U.S. government securities and certificates of deposit with an average maturity of eight years. We mitigate default risk by investing in what we believe are the safest and highest credit quality securities and by monitoring the credit rating of investment issuers. The portfolio includes only marketable securities with active secondary or resale markets to ensure portfolio liquidity and there are limitations regarding duration of investments. These available-for-sale securities are subject to interest rate risk and decrease in market value if interest rates increase. At December 31, 2001, our total portfolio consisted of approximately $25.8 million of investments, with maturities ranging from one to fifteen years. Additionally, we generally hold securities until the earlier of their call or their maturity. Therefore, we do not expect our results of operations or cash flows to be materially impacted due to a sudden change in interest rates. We have $2.8 million in outstanding debt at December 31, 2001 related to the acquisition of THM. FORWARD-LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS This document and other documents we have filed with the Securities and Exchange Commission (SEC) have forward-looking statements. In addition, our senior management may make forward-looking statements orally to analysts, investors, the media and others. Forward-looking statements might include one or more of the following: - Projections of revenues, income earnings per share, capital expenditures, capital structure or other financial items; - Descriptions of plans or objectives of management for future operations, products or services, including future acquisition objectives; - Forecasts of future economic performance; and - Descriptions of assumptions underlying or relating to any of the foregoing Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as "believe", "expect", "anticipate", "intend", "plan", "estimate", or words of similar meaning, or future conditional verbs such as "will", "would", "should", "could" or "may". Such statements give our expectations or predictions of future conditions, events or results. They are not guarantees of future performance. By their nature, forward-looking statements are subject to risks and uncertainties. There are a number of factors, many of which are beyond our control, that could cause actual conditions, events or results to differ significantly from those described in the forward-looking statements. Some of these factors are described as "Risks Related to our Business" below. Factors relating to the regulation and supervision of our company are also described or incorporated in our Annual Report on Form 10-K filed with the SEC. There are other factors besides those described or incorporated in this report or in the Form 10-K that could cause actual conditions, events or results to differ from those in the forward-looking statements. Forward-looking statements speak only as of the day they are made. We do not undertake to publicly update or revise forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. RISKS RELATED TO OUR BUSINESS There are many risk factors that could adversely affect our business, operating results and financial condition. These risk factors, described in detail in our Annual Report on Form 10-K, include but are not limited to: - the continued growth and success of our biomaterials products; - our dependence on our biomaterials customers for marketing and obtaining regulatory approval for their products; - successful commercialization of the Tri-Activ system in the European community; 16 - our ability to obtain regulatory approval for the TriActiv system in the United States; - subsequent to regulatory approval, the successful commercialization of the TriActiv system; - our reliance on revenues from the Angio-Seal product line; - the performance of St. Jude Medical as the manufacturer, marketer and distributor of the Angio-Seal product; - our ability to obtain any additional required funding for future development and marketing of the TriActiv product as well as our biomaterials products; - the competitive markets for our products and our ability to respond more quickly than our competitors to new or emerging technologies and or changes in customer requirements; - the acceptance of our products by the medical community; - our dependence on key vendors and key personnel; - the use of hazardous materials which could expose us to future environmental liabilities; - our failure to expand our management systems and controls to support anticipated growth; - the ownership of our stockholders may be diluted by future acquisitions or strategic alliances; - risks related to our intellectual property, including patent and proprietary rights and trademarks; and - risks related to our industry including potential for litigation, ability to obtain reimbursement for our products and our products exposure to extensive government regulation. Statements contained in this Form 10-Q that are not historical facts are forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution that a number of important factors could cause our actual results for fiscal year 2002 and beyond to differ materially from those in any forward-looking statements made by us or on our behalf. These important factors include, without limitation, the success of our biomaterials products, our ability to obtain the necessary regulatory approvals for, fund and commercialize the TriActiv system, the success of St. Jude Medical in manufacturing, marketing and distributing the Angio-Seal product line, the ability of our customers to market and obtain regulatory approvals for their biomaterials products, the acceptance of our products by the medical community, our ability to maintain key vendors and personnel, competition in our markets, general business conditions in the healthcare industry and general economic conditions. Our results of operations in any past period should not be considered indicative of the results to be expected for future periods. Fluctuations in operating results may also result in fluctuations in the price of our common stock. 17 PART II - OTHER INFORMATION ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K. A. Exhibits. 10.15 Form of Executive Officer Employment Agreement B. Reports on Form 8-K. None 18 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KENSEY NASH CORPORATION Date: February 14, 2002 By: /s/ Wendy F. DiCicco ---------------------------------- Wendy F. DiCicco Chief Financial Officer 19